FRANCESCO FICI, BAHAR ARİCAN TARIM, GOKHAN FAIKOGLU, ELİF ILKAY YUCE, BARİS GUNGOR, NİCOLAS ROBERTO ROBLES
Acta Pharmaceutica Sciencia - 2021;59(4):655-669
Dyslipidemia is the leading cause of cardiovascular mortality and morbidity. Reduction of lipids, particularly low- density lipoprotein cholesterol (LDL-C), with statins, significantly decreases the risk of cardiovascular events. Among different statins, pitavastatin, exhibits a peculiar pharmacokinetic and pharmacological profile. Indeed, differently from other statins, pitavastatin: a) is not metabolized by hepatic cytochrome CYP3A4 isoenzyme, therefore has a very low drug-drug interaction; b) has a similar or greater effect on LDL-C, c) is not associated with glucose metabolism impairment, and the risk of new onset diabetes is very low, d) increases high density lipoproteins (HDL) levels and, particularly, improves cholesterol efflux capacity of HDL, d) decreases cardiovascular outcome in primary and secondary prevention.
